Viatris Guides FY24 In Line With Estimates - Update

RTTNews | Pred 447 dňami
Viatris Guides FY24 In Line With Estimates - Update

(RTTNews) - While reporting financial results for the fourth quarter on Wednesday, healthcare company Viatris Inc. (VTRS) initiated its adjusted earnings and revenue guidance for the full-year 2024.

For fiscal 2024, the company now projects adjusted earnings in a range of $2.70 to $2.85 per share on total revenues between $15.25 billion and $15.75 billion.

On average, seven analysts polled by Thomson Reuters expect the company to report earnings of $2.81 per share on net sales of $15.30 billion for the year. Analysts' estimates typically exclude special items.

On Monday, the company announced that its Board of Directors approved a 2024 dividend policy of $0.48 per share and declared a quarterly dividend of $0.12 for each issued and outstanding share of the Company's common stock, payable on March 18, 2024, to shareholders of record at the close of business on March 11, 2024.

The Company also announced that its Board of Directors authorized a $1.0 billion increase to its share repurchase program and now authorizes the repurchase of up to $2.0 billion of the Company's shares of common stock.

For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com

read more
Viatris Announces US Commercial Launch Of RYZUMVl 0.75%

Viatris Announces US Commercial Launch Of RYZUMVl 0.75%

Healthcare company Viatris Inc. (VTRS) announced Monday the U.S. commercial launch of RYZUMVI (phentolamine ophthalmic solution) 0.75% for the treatment of pharmacologically-induced mydriasis produced by adrenergic agonists (e.g., phenylephrine) or parasympatholytic (e.g., tropicamide) agents in the U.S.
RTTNews | Pred 414 dňami
Viatris Reaffirms FY22 Revenue Outlook, Declares Dividend - Update

Viatris Reaffirms FY22 Revenue Outlook, Declares Dividend - Update

While reporting financial results for the third quarter on Monday, healthcare company Viatris Inc. (VTRS) reaffirmed its total revenue guidance for the full-year 2022 to solid operating momentum despite foreign exchange headwinds and absorbing inflation impact to date.
RTTNews | Pred 925 dňami
U.S. District Court Rules In Favor Of Merck In Patent Infringement Suit Against Viatris

U.S. District Court Rules In Favor Of Merck In Patent Infringement Suit Against Viatris

Merck (MRK), known as MSD outside of the United States and Canada, announced Thursday that the U.S. District Court for the Northern District of West Virginia ruled in favor of the company in a patent infringement suit against Viatris, Inc. (VTRS) related to sitagliptin, an active ingredient in JANUVIA, JANUMET and JANUMET XR.
RTTNews | Pred 971 dňami
Viatris Trims FY22 Revenue Outlook, Declares Dividend - Update

Viatris Trims FY22 Revenue Outlook, Declares Dividend - Update

While reporting financial results for the second quarter on Monday, healthcare company Viatris Inc. (VTRS) trimmed its total revenue guidance for the full-year 2022 to reflect the incremental impact of foreign exchange.
RTTNews | Pred 1016 dňami
Honda Cuts EV Sales, Investment Targets As It Shifts Focus

Honda Cuts EV Sales, Investment Targets As It Shifts Focus

Honda Motor Co., Ltd. announced Tuesday that it is realigning automobile business strategy, with a cut in planned electric vehicle or EV sales ratio, and investment for automobile electrification due to the recent market slowdown. Meanwhile, Honda expects a minimal increase in investment related to Hybrid Electric Vehicle or HEV business.
RTTNews | Pred 53 minútami